Literature DB >> 19032356

Immunoglobulin E antibodies enhance pulmonary inflammation induced by inhalation of a chemical hapten.

C B Mathias1, E-J Freyschmidt, H C Oettgen.   

Abstract

BACKGROUND: Occupational exposure to chemicals is an important cause of asthma. Recent studies indicate that IgE antibodies enhance sensitization to chemicals in the skin.
OBJECTIVE: We investigated whether IgE might similarly promote the development of airway inflammation following inhalation of a contact sensitizer.
METHODS: A model of chemical-induced asthma is described in which introduction of the low-molecular-weight compound, trinitrobenzene sulphonic acid (TNBS), via the respiratory tract was used for both sensitization and challenge. The role of IgE antibodies in the immune response to inhaled TNBS in this model was assessed by comparing the responses of wild-type (WT) and IgE-deficient (IgE(-/-)) mice on the BALB/c background. Reconstitution of circulating IgE levels by intravenous injection of IgE antibodies into IgE(-/-) mice before sensitization was performed to confirm the role of IgE in any differences observed between the responses of WT and IgE(-/-) mice.
RESULTS: Intranasal challenge of TNBS-sensitized (but not sham-sensitized control mice) induced intense pulmonary inflammation. Macrophages, eosinophils and lymphocytes, including T, B, natural killer and natural killer T cells, were recruited to the airway and the animals displayed bronchial hyperresponsiveness (BHR) to methacholine. Serum levels of murine mast cell protease-1 (mMCP-1) were elevated suggesting mast cell activation. In contrast, the development of airway inflammation, recruitment of lymphocytes, induction of BHR and production of mMCP-1 were all significantly attenuated in IgE-deficient mice. Reconstitution of IgE(-/-) mice with IgE (of unrelated antigen specificity) before sensitization partially restored these features of asthma.
CONCLUSION: Our data indicate that IgE antibodies non-specifically enhance the development of airway inflammation induced by exposure to chemical antigens.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19032356     DOI: 10.1111/j.1365-2222.2008.03140.x

Source DB:  PubMed          Journal:  Clin Exp Allergy        ISSN: 0954-7894            Impact factor:   5.018


  6 in total

Review 1.  Concordance of preclinical and clinical pharmacology and toxicology of monoclonal antibodies and fusion proteins: soluble targets.

Authors:  Pauline L Martin; Peter J Bugelski
Journal:  Br J Pharmacol       Date:  2012-06       Impact factor: 8.739

Review 2.  Developments in the field of allergy in 2009 through the eyes of Clinical and Experimental Allergy.

Authors:  H W Chu; C M Lloyd; W Karmaus; P Maestrelli; P Mason; G Salcedo; J Thaikoottathil; A J Wardlaw
Journal:  Clin Exp Allergy       Date:  2010-11       Impact factor: 5.018

Review 3.  Beyond immediate hypersensitivity: evolving roles for IgE antibodies in immune homeostasis and allergic diseases.

Authors:  Oliver T Burton; Hans C Oettgen
Journal:  Immunol Rev       Date:  2011-07       Impact factor: 12.988

4.  Clonal differences in IgE antibodies affect cutaneous anaphylaxis-associated thermal sensitivity in mice.

Authors:  Madison Mack; Elena Tonc; Alyssa Ashbaugh; Abigail Wetzel; Akilah Sykes; Camilla Engblom; Estela Shabani; Carolina Mora-Solano; Anna Trier; Linnea Swanson; Emily Ewan; Tijana Martinov; Devavani Chatterjea
Journal:  Immunol Lett       Date:  2014-08-19       Impact factor: 3.685

5.  Evaluation of serum immunoglobulin E levels in bronchial asthma.

Authors:  Thirunavukkarasu Sandeep; Mysore Subrahmanyam Roopakala; Chickballapur Rayappa Wilma Delphine Silvia; Srikantaiah Chandrashekara; Mohan Rao
Journal:  Lung India       Date:  2010-07

6.  Roles of basophils and mast cells infiltrating the lung by multiple antigen challenges in asthmatic responses of mice.

Authors:  T Nabe; K Matsuya; K Akamizu; M Fujita; T Nakagawa; M Shioe; H Kida; A Takiguchi; H Wakamori; M Fujii; K Ishihara; S Akiba; N Mizutani; S Yoshino; D D Chaplin
Journal:  Br J Pharmacol       Date:  2013-05       Impact factor: 8.739

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.